Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

In the TOURMALINE-MM3 study, post-autologous stem cell transplantation maintenance therapy with the oral proteasome inhibitor ixazomib versus placebo significantly improved progression-free survival (PFS), with a favorable safety profile. With ixazomib versus placebo maintenance, deepening responses occurred in 139/302 (46%) versus 60/187 (32%) patients with very good partial response or partial response (VGPR/PR) at study entry (relative risk 1.41, P = 0.004), and median time to best confirmed deepened response was 19.9 versus 30.8 months (24-month rate: 54.2 versus 41.4%; hazard ratio (HR): 1.384; P = 0.0342). Median PFS in patients with VGPR/PR at study entry was 26.2 versus 18.5 months (HR: 0.636, P 

Original publication

DOI

10.1038/s41375-020-0819-8

Type

Journal article

Journal

Leukemia

Publication Date

11/2020

Volume

34

Pages

3019 - 3027

Keywords

Adult, Aged, Antineoplastic Agents, Boron Compounds, Combined Modality Therapy, Female, Glycine, Hematopoietic Stem Cell Transplantation, Humans, Kaplan-Meier Estimate, Maintenance Chemotherapy, Male, Middle Aged, Multiple Myeloma, Neoplasm Staging, Postoperative Care, Treatment Outcome, Young Adult